Skip to main content




UK starts Moderna COVID-19 jabs as AstraZeneca probed

UK starts Moderna COVID-19 jabs as AstraZeneca probed

A person holds a vial of the Moderna COVID-19 vaccine at a care home in Naples, Italy, on Mar 30, 2021. (File photo: Reuters/Ciro De Luca)

LONDON: The United Kingdom on Wednesday (Apr 7) began rolling out its third COVID-19 vaccine, from American company Moderna, as questions mounted over jabs from the country's main supplier, AstraZeneca.

The Moderna vaccine, which is already being delivered in Europe and the United States, joined ones from AstraZeneca-Oxford University and Pfizer-BioNTech in Britain's armoury against the coronavirus.

The first jab of the two-stage Moderna inoculation was given at a hospital in Wales to 24-year-old Elle Taylor.

"I'm an unpaid carer for my grandmother, so it is very important to me that I get it, so I can care for her properly and safely," she told reporters.

Taylor said she would have been happy to take the AstraZeneca jab despite adverse publicity, centred in Europe, surrounding blood clots.

"I had heard, but it doesn't concern me too much. And I guess if it happens, it happens, and I am in the right care if I need it, and I feel happy that I've tried the new one," she said.

The arrival of the Moderna inoculation represents a timely diversification of Britain's roll-out, and was hailed by Prime Minister Boris Johnson.

"We have ordered 17 million doses that will be going into arms across the UK in the coming weeks. Please get your jab as soon as you are contacted," he tweeted.

Supply problems for AstraZeneca had threatened to complicate Britain's inoculation drive this month, and concerns are building over a potential link between the jab and rare blood clots among a small number of recipients.

READ: UK COVID-19 vaccine supply is challenging but targets will be met, minister says

READ: UK's Boris Johnson confirms return to pubs but sounds caution on travel


Oxford University said late on Tuesday that it had paused a British trial of the AstraZeneca vaccine on children.

The university said the trial had posed "no safety concerns", but that it was awaiting more data from Britain's Medicines and Healthcare products Regulatory Agency (MHRA) before restarting the study.

The MHRA says it is looking into the cases of clotting, amid reports that the regulator may join some countries in the European Union in restricting access in younger age groups.

The MHRA reported at the weekend that there had been 30 blood clotting cases, seven fatal, out of 18 million doses administered in Britain.

The European Medicines Agency (EMA) is also looking anew at the issue, but so far the World Health Organization insists the jab is safe.

Kent Woods, a British former head of both the MHRA and EMA, told LBC radio that the risks of COVID-19 were much higher, and he had "no reservations" about the AstraZeneca vaccine.

But Maggie Wearmouth, a member of the government's Joint Committee on Vaccination and Immunisation, told the Daily Telegraph that "perhaps slowing things down" with the roll-out might be wise until any safety concerns are dispelled.

Any delays could imperil the British government's phased easing of its current coronavirus lockdown, with all adults due to receive a first vaccine dose by the end of July.

More than 31.6 million first doses of either the AstraZeneca or Pfizer vaccines have been given out, representing three out of every five adults.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:

Source: AFP/kg


Also worth reading